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Abstract
Background: Estimation of cardiovascular disease risk is increasingly used to inform decisions on
interventions, such as the use of antihypertensives and statins, or to communicate the risks of
smoking. Crude 10-year cardiovascular disease risk risks may not give a realistic view of the likely
impact of an intervention over a lifetime and will underestimate of the risks of smoking. A validated
model of survival to act as a decision aid in the consultation may help to address these problems.
This study aims to describe the development of such a model for use with people free of
cardiovascular disease and evaluates its accuracy against data from a United Kingdom cohort.
Methods: A Markov cycle tree evaluated using cohort simulation was developed utilizing
Framingham estimates of cardiovascular risk, 1998 United Kingdom mortality data, the relative risk
for smoking related non-cardiovascular disease risk and changes in systolic blood pressure and
serum total cholesterol total cholesterol with age. The model's estimates of survival at 20 years for
1391 members of the Whickham survey cohort between the ages of 35 and 65 were compared
with the observed survival at 20-year follow-up.
Results: The model estimate for survival was 75% and the observed survival was 75.4%. The
correlation between estimated and observed survival was 0.933 over 39 subgroups of the cohort
stratified by estimated survival, 0.992 for the seven 5-year age bands from 35 to 64, 0.936 for the
ten 10 mmHg systolic blood pressure bands between 100 mmHg and 200 mmHg, and 0.693 for the
fifteen 0.5 mmol/l total cholesterol bands between 3.0 and 10.0 mmol/l. The model significantly
underestimated mortality in those people with a systolic blood pressure greater than or equal to
180 mmHg (p = 0.006).
The average gain in life expectancy from the elimination of cardiovascular disease risk as a cause of
death was 4.0 years for all the 35 year-old men in the sample (n = 24), and 1.8 years for all the 35
year-old women in the sample (n = 32).
Conclusions: This model accurately estimates 20-year survival in subjects from the Whickham
cohort with a systolic blood pressure below 180 mmHg.
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Background
The evaluation of the risk of developing coronary heart
disease (CHD) is increasingly used as a basis for making
treatment decisions to prevent cardiovascular disease
(CVD). Internationally, the most established measure is
the Framingham risk [1] for developing CHD over a 10-
year period [2-4]. Such measures also have some value as
a means of communicating risk to individuals in consul-
tations. This facilitates patient participation in treatment
decisions and can help inform advice about the risks of
smoking. However, there are weaknesses to this approach.
A common approach is to use a 15% 10-year risk of CHD
as a threshold for using antihypertensive drugs in people
with a systolic BP between 140 and 160 mmHg [3,4].
However, there are weaknesses to using simple absolute
CHD risk without consideration of other factors [5]. Car-
diovascular risk increases with age and so the elderly more
often cross this treatment threshold. Most other causes of
death also increase with age and life expectancy reduces
with age. Given that the benefits of treatment are accrued
over time, younger patients with a lower risk of CHD, but
a greater life expectancy might have more to gain from
treatment. Also when communicating the risks of smok-
ing, the CHD risk is an underestimate of the true risks of
smoking because of the wide variety of other pathologies
that it causes.
The 10-year Framingham CHD risk for an individual only
gives a crude idea of the likely impact of treatment or
smoking cessation on an individual's life as it does not
take into account the impact of competing causes of
death, in particular other significant causes of mortality
related to smoking. Other Markov models have been
developed to assess the impact of cardiovascular disease
mortality [6] or to evaluate the cost-effectiveness of treat-
ment [5], but most do not take into account the relative
risks of non-cardiovascular death for smokers compared
to non-smokers [7-10], or model survival in populations
rather than individuals [11]. Grover et al developed a
model based on the Lipid Research Clinics program which
makes some adjustment for the relative risks of smoking
[12]. It has been validated against a number of interven-
tion trials showing that its predictions of survival correlate
highly with the observed survival. A Markov cycle tree
evaluated using cohort simulation was developed to esti-
mate survival over a lifetime. The model uses the Framing-
ham equations for calculating CVD risks. The model also
takes into account non-cardiovascular competing causes
of death and models the changes in CHD risk factors with
age. A Markov cycle tree structure was used because of the
complex variety of pathways between the starting 'well'
state and the absorptive 'dead' state [13].
The model presented in this paper takes into account
competing causes of death, changes in risk factors with age
and the relative risks of smoking on non-CVD mortality.
It can estimate the probability of survival (between 0.0
and 1.0) at annual increments from the start age to the age
of 85. Before such a model could be used in clinical prac-
tice to inform treatment decisions, it is important that
some measure of its predictive accuracy is obtained.
This study uses data from the Whickham study [14,15] to
assess the accuracy of the model at predicting survival in
this cohort at twenty years. The original Whickham study
was conducted between 1972 and 1974 in a mixed urban
and rural area close to Newcastle upon Tyne. The cohort
included 2779 adults aged over the age of 18 years, ran-
domly identified to generate a sample that closely
matched the United Kingdom (UK) population in terms
of age, gender and social class. The original data set
included blood pressure (BP), electrocardiogram (ECG)
and serum total cholesterol (TC), thus allowing its use for
Framingham equations. A 20-year follow-up study was
also conducted which collected further data on the inci-
dence of thyroid disorders and also collected data on mor-
bidity and mortality.
Methods
Absolute, annual non-CVD risk of death were derived by
linear interpolation from the UK National mortality sta-
tistics for 1998 [16]. The risks for those causes of death
that were smoking related were adjusted for smokers and
non smokers using the relative risks from the 4-year fol-
low-up of the US Cancer Society's 50-state study (CPS-II)
quoted in the US Surgeon General's report of 1989 (Table
1) [17].
These relative risks were used to adjust the death rates
from smoking related causes of death using the formula
below:
RS = Y.M/(S.(Y-1) + 1) (for smokers)
RN = M/(S.(Y-1) + 1) (for non-smokers)
Where:
Y = Relative risk for smokers.
S = Proportion of smokers.
RN = Absolute risk for non-smokers.
RS = Absolute risk for smokers.
M = Mortality rate per person.
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The proportion of smokers at each age for each sex was
taken from the Health Survey for England 1998 [18]. A
similar formula was used by Pharoah in his life table
modelling intervention with statins [10].
The model used the Framingham risks for CHD and
stroke rather than the Framingham risk for CVD death as
this accounted for the majority of CVD deaths and was
easier to map to the UK mortality statistics. The annual
risks for the various CVD risks included in the model were
calculated by taking one quarter of the 4-year Framing-
ham risk [1]. The 4-year Framingham risk was used as this
is the shortest period calculable using the Framingham
equation.
For the states 'Survived a myocardial infarction (MI)', 'Sur-
vived other CHD', 'Survived a stroke' and 'Survived other
CVD' the risk of death is estimated by taking the Framing-
ham risk for that individual and multiplying it with the
corresponding relative risk in Table 2.
Model structure
Six states are modelled: 'Alive and well', 'Survived an MI',
'survived other CHD ', 'survived a stroke', 'survived other
CVD' and 'Dead'. The state 'survived other CHD' would
largely consist of those who develop angina without first
suffering an MI. The state 'survived other CVD' would con-
sist of other CVD states such as intermittent claudication.
Their relationships are shown in the state transition dia-
gram in Figure 1. There is no transfer between the four
states representing survival of a cardiovascular event and
there is a modelling assumption that the risk of death is
not increased by further cardiovascular events.
The basic method used by the model is outlined in the
Markov cycle-tree in Figure 2[13]. The activity diagram is
shown in Figure 3. The time horizon of the model is to the
age of 85, and the cycle length is one year. Through the
lifetime of the individual, the model adjusts the BP and
TC using the change in mean BP for each year derived
from the 'Health Survey for England: cardiovascular
disease in 1998' [18]. It was implemented using the
Microsoft Excel™ spreadsheet package.
The model estimates survival for an individual between
35 and 75. It starts at the current age of the individual,
estimating mortality in each successive year, up to the
Table 1: Smoking-related, non-CVD mortality and the relative risk used for smokers quoted by the US Surgeon General's report of 1989 
based on the 4-year follow-up of the US Cancer Society's 50-state study (CPS-II) [17].
Cause of death Relative risk for smokers
Males Females
COPD 9.65 10.47
Other Respiratory 1.99 2.18
Carcinoma Oesophagus 7.6 10.25
Carcinoma Pancreas 2.14 2.33
Carcinoma Larynx 10.48 17.78
Carcinoma Lung 22.36 11.94
Carcinoma Cervix - 2.14
Carcinoma Kidney 2.95 1.41
Carcinoma Bladder/other urinary 2.86 2.58
Carcinoma Lip, Oral cavity, Pharynx 27.48 5.59
Table 2: The relative risks of death for those with existing CVD used by the model.
Disease state Relative risk Derivation
Previous MI. 6.0 Pharoah et al [10]
Existing CHD excluding MI. 2.4
Previous stroke. 1.56 Estimated using the reciprocal of the life expectancy ratios calculated for stroke survivors in 1994 by 
Hannertz et al [25]
Other existing CVD. 2.0 2.0 used as no suitable reference was identified and this figure is approximately half way between 
1.56 (stroke) and 2.4 (CHD).
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State transition diagram for the six states in the modelFigure 1
State transition diagram for the six states in the model.
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Markov cycle tree outlining the structure of the modelFigure 2
Markov cycle tree outlining the structure of the model.
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An activity diagram outlining the structure of the modelFigure 3
An activity diagram outlining the structure of the model.
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time horizon of the age of 85 years taking account of the
risk factors in Table 3.
Validation
All cases within the Whickham data set were identified
between the ages of 35 and 65 and the risk factors
described in Table 3 were extracted. Absence of left ven-
tricular hypertrophy (LVH) and an average high density
lipoprotein (HDL) of 1.3 for males and 1.6 for females
was assumed as these are the approximate averages in the
Health Survey for England: CVD in 1998 [18].
Cases with missing data or any kind of heart disease or
cerebrovascular disease at baseline were excluded. The
model estimate of the probability of survival for each case
was identified at 20 years. Once the survival probabilities
had been generated the average actual survival was calcu-
lated by finding the proportion of the cohort still alive at
20 years. The average probability of survival was calcu-
lated by finding the mean of all the estimated 20-year sur-
vival probabilities generated by the model.
Further analysis was conducted by sorting and grouping
subjects in the order of their rank for each factor in Table
4. The mean actual survival in each group of these subjects
was plotted against the mean estimated survival probabil-
ity at 20 years.
The biological and measurement variability of BP and TC
are significant. A sensitivity analysis for these two factors
was conducted. For systolic BP, a total coefficient of varia-
tion (CVT) of 5.6% was taken [19] giving 95% confidence
intervals (95% CI) of approximately +/- 11%. For TC, a
CVT of 7.4% was used giving approximate 95% CI of +/-
15%. A grid of 12 hypothetical subjects of the ages 35, 50
and 65 with gender and smoking status was drawn up
Table 3: The risk factors used in the Framingham risk equations.
Age
Gender
Smoking status
Systolic or diastolic BP
Serum total cholesterol/high density lipoprotein ratio
Presence of diabetes
Presence of left ventricular hypertrophy
Table 4: Groupings used for determining correlations between the model predictions and actual mortality rates in the Whickham 
study.
Ranking factor Grouping
Model estimates of 20-year survival 39 groups of 35 subjects and 1 of 29
Age (1) One year age bands
Age (2) Five year age bands
Systolic BP 10 mm Hg bands from 100 to 200 mm Hg
TC 0.5 mmol/l bands from 3.0 to 9.99 mmol/l.
Table 5: Summarising the comparison of the model survival estimates with actual survival in the Whickham cohort.
n Model Whickham Difference Diff 95%CI Significant difference? P =
Total 1391 75.0% 75.4% 0.4% -1.6%, 2.4% 0.764
Sex Men 676 70.0% 71.3% 1.3% -1.7%, 4.2% 0.402
Women 715 79.8% 79.3% -0.5% -3.2%, 2.3% 0.747
Age 35–50 783 63.1% 63.1% 0.0% -3.2%, 3.1% 0.976
>50 608 58.4% 58.2% -0.2% -3.9%, 3.5% 0.914
Smoking status Smokers 709 68.4% 69.4% 1.0% -2.0%, 4.1% 0.525
Non-smokers 683 81.9% 81.7% -0.3% -2.9%, 2.3% 0.849
Total cholesterol TC >= 7.5 170 68.3% 65.3% -3.0% -9.6%, 3.6% 0.447
TC 5.5–7.4 827 75.2% 76.4% 1.2% -1.4%, 3.7% 0.447
TC < 5.5 284 77.6% 75.1% -2.5% -9.0%, 4.0% 0.338
Systolic BP BP >= 180 95 55.6% 40.4% -15.2% -24.4%, -5.9% 0.006
BP 160–179 180 63.3% 66.1% 2.8% -3.3%, 9.0% 0.458
BP 115–159 1000 77.7% 78.7% 1.0% -1.3%, 3.3% 0.467
BP < 115 115 86.1% 89.7% 3.5% -1.9%, 9.0% 0.259
Diabetes Diabetic 9 71.4% 55.6% -15.8% -43.6%, 12.0% 0.413
Non-diabetic 1382 75.0% 75.5% 0.4% -1.6%, 2.5% 0.729
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using a systolic BP of 135 mmHg for the TC sensitivity
analysis and a TC of 5.5 mmol/l for the systolic BP sensi-
tivity analysis.
A sub-group analysis was performed to examine the per-
formance of the model in the sub-groups in Table 5.
The model was used to estimate the potential gains in life
expectancy (PGLE) from the elimination of CVD as a
cause of death. Half cycle correction was used [13]. This
was firstly done on an typical example 35 year-old non-
smoking man and 35 year-old woman non-smoking with
a systolic BP of 131 mmHg and a TC/HDL ratio of 4.08.
Secondly, the model was used to estimate the PGLE of
each 35-year-old in the Whickham sample to give the
average PGLE's for these men and women at the age of 35
years.
Results and discussion
Of the 2779 people in the Whickham cohort, 1,541 were
between the ages of 35 and 65 inclusive. Of these 8 had
missing data. Another 142 were excluded because of pre-
existing CVD. The results of the subgroup analysis are
shown in Table 5. The correlation between the model's
estimated survival and actual survival are shown in Table
6. Graphs showing the plots of the model's estimates of
survival probability and the average survival in the Whick-
ham cohort for each of the groups analysed in Table 3 are
shown in the Figures 4, 5, 6, 7, 8 and 9.
There is a high level of agreement between the predictions
of the model and the actual survival in the Whickham
cohort. However, as can be seen from the Table 5, the
model statistically significantly underestimates mortality
at twenty years in those people with a systolic BP over 180
mmHg even though there were only 95 cases in that group
(p = 0.006). There were no other significant differences
between the two groups.
The correlations between model estimates of the proba-
bility of survival and actual survival in the specified
groupings are given in Table 6. The results of the sensitiv-
ity analysis are given in Table 7.
The PGLE for our typical 35 year-old man was 2.7 years
and 1.8 years for our typical 35-year-old woman. For the
twenty-four 35-year-old men in the sample used in the
validation, the average PGLE was 4.0 years. For the thirty-
two 35-year-old women the PGLE was 1.8 years.
Table 6: A comparison of the model's predictions and actual 
survival.
Ranking factor Correlation
Model estimates of 20-year survival (40 groups) 0.933
Age (1-year bands) 0.955
Age (5-year bands) 0.992
Systolic BP (bands of 10 mmHg) 0.936
TC (bands of 0.5 mmol/l) 0.693
Table 7: Sensitivity analysis for uncertainties in systolic BP and TC and their measurement. The three hypothetical BPs given are 
adjusted by +/- 11% and the TCs by +/- 15%. A 'normal' BP of 135 mmHg systolic is assumed for the TC analysis and a 'normal' cholesterol 
of 5.5 mmol/l is taken for the BP analysis. Values for the predicted survival at 20 years are given.
Systolic BP mmHg (95% CI) TC mmol/l (95% CI)
120 (107 – 133) 140 (125 – 155) 160 (142 – 178) 4.0 (3.4 – 4.6) 6.0 (5.1 – 6.9) 8.0 (6.8 – 9.2)
35 year old man S 94.2 – 92.9 93.4 – 90.9 92.2 – 88.0 94.0 – 93.3 93.0 – 91.5 91.6 – 89.0
NS 96.0 – 95.5 95.7 – 94.6 95.2 – 93.3 95.8 – 95.6 95.5 – 94.9 95.0 – 93.9
35 year-old woman S 95.3 – 95.3 95.3 – 95.2 95.3 – 95.1 95.4 – 95.3 95.3 – 95.2 95.2 – 94.9
NS 96.9 – 96.9 96.9 – 96.8 96.9 – 96.8 96.9 – 96.9 96.9 – 96.9 96.9 – 96.8
50 year old man S 73.0 – 68.3 69.9 – 63.0 66.2 – 56.7 72.8 – 70.1 68.9 – 64.0 64.3 – 57.8
NS 84.9 – 82.4 83.3 – 79.2 81.2 – 74.8 84.7 – 83.4 82.8 – 79.9 80.1 – 75.5
50 year-old woman S 79.6 – 79.3 79.4 – 78.7 79.1 – 77.7 79.9 – 79.6 79.4 – 78.5 78.5 – 76.7
NS 89.1 – 89.0 89.0 – 88.8 88.9 – 88.5 89.2 – 89.1 89.0 – 88.7 88.7 – 88.0
65 year old man S 16.8 – 14.7 15.4 – 12.7 13.9 – 10.6 16.8 – 15.5 14.9 – 13.1 13.2 – 11.2
NS 50.3 – 46.4 47.8 – 42.3 44.8 – 37.5 50.3 – 48.8 47.0 – 43.0 43.2 – 38.2
65 year-old woman S 37.1 – 36.7 36.9 – 36.0 36.5 – 35.1 37.7 – 37.2 36.9 – 35.6 35.7 – 33.7
NS 63.6 – 63.3 63.5 – 62.8 63.2 – 62.0 64.0 – 63.7 63.5 – 62.5 62.6 – 60.7
S = Smoker NS = Non-smoker
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Discussion
The survival estimated by this model, and the observed
survival in the Whickham study correlate highly. It signif-
icantly overestimates survival in those with a systolic BP of
180 mmHg or more (p = 0.006).
For 50-year-old men the sensitivity analysis shows up to a
9.5% range in the 95% confidence intervals (CI) for the
estimated survival at 20 years based on 3 BP readings and
a 6.5% range based on a single measurement of the TC.
Otherwise the 95% CI do not exceed +/- 2% of the mean.
This would underline the need to take more than 3 BP
readings and at least two serum TC measurement in mid-
dle aged men.
This model is focused on individuals and is not a popula-
tion simulation as is the CHD Policy Model [6]. Conse-
quently it can be used to give individualised risk
information in real time. Grover et al used data from the
Lipid Research Clinics cohort and included a multivariate
model for death from 'other causes' in addition to CHD
and stroke and so took account of competing causes of
death [12]. In addition to modelling competing risk of
death, the model described here adjusts the risks of non-
cardiovascular death by smoking status and also models
the change in BP and cholesterol through a lifetime.
This system may be of value in the development of public
health programs where different intervention and
prevention strategies could be modelled giving reliable
estimates of the impact on survival. The inclusion of an
adjustment for the non-CVD risks of death from smoking
is particularly important here, as these competing causes
of death will have a greater impact in smokers than in
non-smokers.
Tools such as these will naturally be attractive to insurers
for actuarial assessment but their use may be
controversial. The model may reduce uncertainty in sur-
vival in certain groups and reduce risk in setting the levels
of premiums. However, this could be regarded as
Scatterplot of the estimated probability of survival against the actual survival in the subjects grouped into seven 5-year age bands between 35 and 65 years oldFigure 4
Scatterplot of the estimated probability of survival against the actual survival in the subjects grouped into seven 5-year age 
bands between 35 and 65 years old.
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undermining the very principles on which insurance is
based – uncertainty and the sharing of risk.
The weaknesses of the model and further development
Historical variation and the effect on conclusions of validity
The Framingham equations used here were developed
from cohort data collected in the 1960s and 1970s. We
know that since then there has been a fall in the incidence
of CHD mortality and a change in the prevalence of smok-
ing. Whilst it may be that the change in incidence is due
to the change in the prevalence of risk factors included in
the Framingham equation, we cannot be sure that there
are not other extraneous factors that have varied over that
time and may have affected the incidence of CHD. If so,
the validity of the Framingham equation in modern pop-
ulations may be undermined. For example, some other
risk factor such as serum fibrinogen levels, homocysteine,
soft water, chlamydia infection or an as yet undetected
factor my have altered which would distort the Framing-
ham predictions. It is not just risk factors that are relevant
here, but also protective factors such as a moderate intake
of red wine [20] or exercise [21]. We have used the Whick-
ham survey that collected its 20-year follow-up data in the
early 1990s. This model will be used in individuals at the
beginning of a period of prediction rather than at the end,
so the best we can say is that this model was valid when
making predictions of survival in a UK population 30
years ago when the Whickham data was first being
collected.
Smoking cessation
This model makes a number of assumptions about non-
smokers and smokers that do not quite fit the real world.
These assumptions are that:
• Smokers remain smokers and do not quit.
• Non-smokers have never smoked at all.
Scatterplot of the estimated probability of survival against the actual survival in the subjects grouped into fifty one 1-year age bands between 35 and 65 years oldFigure 5
Scatterplot of the estimated probability of survival against the actual survival in the subjects grouped into fifty one 1-year age 
bands between 35 and 65 years old.
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Plot of the estimated probability of survival and the actual survival in the subjects grouped into seven 5-year age bands between 35 and 65 years oldFigure 6
Plot of the estimated probability of survival and the actual survival in the subjects grouped into seven 5-year age bands between 
35 and 65 years old.
Plot of the estimated probability of survival and the actual survival in the subjects grouped into fifty one 1-year age bands between 35 and 65 yea s oldFigur  7
Plot of the estimated probability of survival and the actual survival in the subjects grouped into fifty one 1-year age bands 
between 35 and 65 years old.
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Plot of the estimated probability of survival and the actual survival in the subjects grouped into ten 10 mmHg bands for systolic BP betwe n 100 an 200 mmHgFigure 8
Plot of the estimated probability of survival and the actual survival in the subjects grouped into ten 10 mmHg bands for systolic 
BP between 100 and 200 mmHg.
Plot of the estimated probability of survival and the actual survival in the subjects grouped into fourteen 0.5 mmol/l bands for total chol sterol (TC) between 3.0 and 10.0 mmol/lFigure 9
Plot of the estimated probability of survival and the actual survival in the subjects grouped into fourteen 0.5 mmol/l bands for 
total cholesterol (TC) between 3.0 and 10.0 mmol/l.
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If this model were to be used to assess the benefits of quit-
ting smoking, it would be on the assumption that a
quitter's risk falls instantly to the risk of non-smokers.
These are clearly invalid assumptions. When evaluating
the survival of smokers it is on the assumption that they
will remain smokers all their life. This impacts upon our
evaluation, because those individuals who were recorded
as smokers at their baseline assessment at time 0 were
assumed to remain smokers until death or their 20-year
follow-up. Clearly many will have given up in the
intervening period. The net results of this would be an
overestimate of mortality in smokers. This is in keeping
with our results that show a small, non-significant overes-
timate of mortality in smokers.
The risks of ex-smokers probably never fall to those of
non-smokers, and the reduction in risk varies with the age
at which you quit. Quitting before middle-age reaps
greater benefit than quitting later in life [22]. It would be
feasible to use the different relative risk for ex-smokers
given in the Surgeon General's report of 1989 to improve
the model for ex-smokers. It would even be possible to
indicate the impact of quitting at various times in the
future.
Modelling intervention
This model can give an indication of life gained with inter-
vention or elimination of CHD and stroke. For example,
our typical 35 year-old, non-smoking man (systolic BP of
131 and a TC/HDL ratio of 4.08) eliminating CHD and
stroke as a cause of death (relative risk reduction of 100%)
would reduce his mortality to the age of 85 of by about
12.1% (Figure 10). This amounts to an average PGLE of
2.71 years. The pale yellow coloured part of the graph in
Figure 10 represents the life gained.
The Coronary Heart Disease Policy Model predicted the
PGLE from eliminating CHD to be 3.1 years for men. This
is in keeping with the predictions of our model. However,
the Coronary Heart Disease Policy Model also predicted a
PGLE of 3.3 years for women. This is actually higher than
the quoted PGLE for men and nearly double the PGLE
The improvement in survival gained from eliminating CVD in a typical non-smoking 35 year-old manFigure 10
The improvement in survival gained from eliminating CVD in a typical non-smoking 35 year-old man.
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predicted by our model. CVD death rates are higher in
men than women across all ages in the UK and so the
model described here would seem more consistent with
the observed epidemiological data [16].
If the forty people aged 55 in this study reduced their risk
of CHD or stroke by 88%, then the PGLE would be 2.2
years. Wald et al in their paper on the Polypill estimated
that a third of 55 year-olds would gain about 11 years free
of CHD events [23]. Their 'simple Markov model' did take
account of CVD as well as of 'dying from another cause'
but had markedly divergent results from this study. This
may reflect the small sample size of 55 year-olds in this
study (n = 40), or a failure of Wald's model to take into
account all of the factors included in this model.
Mackenbach estimated that the PGLE from the elimina-
tion of CVD would be about 4.0 years from birth [24].
This would seem to be in keeping with the results of our
model as the proportion of deaths from CVD prior to the
age of 35 is very small [16]. On the whole it would seem
that the predictions of this model are in keeping with the
bulk of other model estimates of PGLE.
Conclusions
This model gives valid estimates of 20-year survival in
Whickham cohort members between the ages of 35 and
60 who are free of CVD and have systolic BPs below 180
mmHg. It could form the basis of a decision aid in the pri-
mary prevention of CVD. It would be useful in the mod-
elling of intervention and prevention strategies and could
be a valuable tool for actuarial assessment.
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